| Preclinical AD | Biomarker evidence of AD pathology in otherwise cognitively normal individuals |
| Prodromal AD | MCI due to AD with progressive cognitive decline that is still insufficient for dementia diagnosis |
| Dementia due to AD | Progressive cognitive decline impairing functional independence |
| MCI prevalence | 10-20% of adults over age 65 |
| MCI due to AD | Approximately 50-60% of all MCI cases have AD pathology as the primary cause |
| Age distribution | Prevalence increases with age, rare before 65, more common after 75 |
| Annual conversion | Approximately 10-15% of MCI patients progress to dementia annually |
| Amnestic MCI | Higher conversion rate (15-20% annually), particularly those with memory-predominant deficits |
| Non-amnestic MCI | Lower conversion rates, more variable outcomes |
| Biomarker-positive MCI | Higher conversion rates (up to 40% annually for tau-positive individuals)[@petersen2018] |
| Independent daily living | Patients can perform complex instrumental activities of daily living (IADLs) |
| Mild functional changes | May require occasional reminders or assistance with complex tasks |
| Databases | OMIMOrphanetClinicalTrialsPubMed |
No AI portrait yet
No comments yet. Be the first to comment!